TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01452451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HM11260C
Description: 1, 2, and 4 mg for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. 8, 12 and 16 mg for 3 monthly subcutaneous injections for cohorts M1, M2 and M3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. Placebo for 3 monthly subcutaneous injections for for cohorts M1, M2 and M3
Study: NCT01781598

Intervention type: DEVICE
Intervention: Total knee arthroplasty (TKA) (Smith &Nephew®)
Study: NCT04283084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Based Balance and Coordination Exercises
Description: With the developed virtual reality based balance and coordination training system, balance and coordination exercises will be applied twice a week (12 sessions in total) for 6 weeks.
Study: NCT02780687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Study: NCT02629757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: β-elemene
Description: β-elemene 600mg/d,ivdrip,d1-14,every 28 days for 1 cycle, totally 6 cycles
Study: NCT02768064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: temporary pacemaker insertion
Description: Insertion of pacemaker electrode (Medtronic flow direct pacing catheter), connect to external pacemaker (Medtronic).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: temporary pacemaker insertion
Description: Insertion of pacemaker electrode (Medtronic flow direct pacing catheter), connect to external pacemaker (Medtronic).
Study: NCT04343066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant insertion
Description: In both groups, the implants will be placed using a two-stage surgical approach at the crestal level in previously horizontally augmented bony sites.~A final crown will be placed (screw-retained on multiunit abutment) between 3- and 4-months post-implant placement.~Random allocation of implant type per site will be done by the sealed envelope method.~Follow-up measurements will be done at 6 months and 1-year post-loading. The measurements are done by a blinded investigator. Before starting the study, the examiner will be trained in a calibration process.~Exam sheets are kept confidential and anonymous. Inclusion criteria are: patient aged 20 to 65, no systematic contraindication for implant surgery, smoking \< 10 cigarettes, previous horizontal bone augmentation, FMBS \<20% and FMPS \< 20%. Exclusion criteria are: general contraindication for implant surgery, pregnant/lactating women, uncontrolled diabetics, patients not willing to sign the consent form, active periodontitis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant insertion
Description: In both groups, the implants will be placed using a two-stage surgical approach at the crestal level in previously horizontally augmented bony sites.~A final crown will be placed (screw-retained on multiunit abutment) between 3- and 4-months post-implant placement.~Random allocation of implant type per site will be done by the sealed envelope method.~Follow-up measurements will be done at 6 months and 1-year post-loading. The measurements are done by a blinded investigator. Before starting the study, the examiner will be trained in a calibration process.~Exam sheets are kept confidential and anonymous. Inclusion criteria are: patient aged 20 to 65, no systematic contraindication for implant surgery, smoking \< 10 cigarettes, previous horizontal bone augmentation, FMBS \<20% and FMPS \< 20%. Exclusion criteria are: general contraindication for implant surgery, pregnant/lactating women, uncontrolled diabetics, patients not willing to sign the consent form, active periodontitis.
Study: NCT04012632

Intervention type: OTHER
Intervention: this study was an observational study and no interventions were given to the participants
Description: the participants were recruited and the data as well as blood sample were collected.
Study: NCT04285749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Description: Fluvastatin PO 80mg QD for 2 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RNA-sequencing
Description: RNA-sequencing will be completed on the original diagnostic biopsy and the final melanoma excision

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gene expression profiling
Description: Gene expression profiling will be completed on the original diagnostic biopsy and the final melanoma excision
Study: NCT03729297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: cabozantinib tablets (Cabometyx®) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw for a maximum duration of 2 years.
Study: NCT02392897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Eating Frequency
Description: Free-living participants will complete a 21-day high eating frequency (high EF) Phase in which consume all daily energy at 6 eating occasions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Eating Frequency
Description: Free-living participants will complete a 21-day low eating frequency (low EF) Phase
Study: NCT05589415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-definition Transcranial Direct Current Stimulation
Description: High-definition Transcranial Direct Current Stimulation (HD-tDCS) delivers current through five small electrodes (0.8 cm2) placed in an X-shaped configuration via a simple cap. This configuration leads to an 80% greater concentration or focusing of the electric field within the targeted region compared to conventional, non-focal Transcranial Direct Current Stimulation (tDCS). The participant will undergo 30 minutes of treatment at 2 milliamps.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Transcranial Direct Current Stimulation
Description: Surface electrodes will be placed in saline-soaked sponges (5 x 7 cm2) and applied to different regions of the scalp. The participant will undergo 30 minutes of treatment at 2 milliamps.
Study: NCT04549584

Intervention type: DIAGNOSTIC_TEST
Intervention: Vimentin/pan CK stain
Description: Vimentin/pan CK stain positive/negative
Study: NCT00540501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir and Intravenous Zanamivir
Description: Oseltamivir will be administered PO q12h for 3 days (for a total of 5 doses ending the morning of day 3.~Both drugs will be administered simultaneously starting on Day 1 of Period 3. Zanamivir will be administered IV q12h for 3 days (for a total of 5 doses ending on the morning of day 3.~Zanamivir to be given four (4) hours after the oral dose of oseltamivir and infused over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir and Intravenous Zanamivir
Description: Oseltamivir will be administered PO q12h for 3 days (for a total of 5 doses ending the morning of day 3.~Both drugs will be administered simultaneously starting on Day 1 of Period 3. Zanamivir will be administered IV q12h for 3 days (for a total of 5 doses ending on the morning of day 3.~Zanamivir to be given four (4) hours after the oral dose of oseltamivir and infused over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir and Intravenous Zanamivir
Description: Oseltamivir will be administered PO q12h for 3 days (for a total of 5 doses ending the morning of day 3.~Both drugs will be administered simultaneously starting on Day 1 of Period 3. Zanamivir will be administered IV q12h for 3 days (for a total of 5 doses ending on the morning of day 3.~Zanamivir to be given four (4) hours after the oral dose of oseltamivir and infused over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir and Intravenous Zanamivir
Description: Oseltamivir will be administered PO q12h for 3 days (for a total of 5 doses ending the morning of day 3.~Both drugs will be administered simultaneously starting on Day 1 of Period 3. Zanamivir will be administered IV q12h for 3 days (for a total of 5 doses ending on the morning of day 3.~Zanamivir to be given four (4) hours after the oral dose of oseltamivir and infused over 30 minutes.
Study: NCT04457843

Intervention type: OTHER
Intervention: usual medical care
Description: Prospective monitoring of clinical Outcomes and digital collected outcomes via the mobile COPD staus test app.
Study: NCT01631565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early allocation to palliative care
Description: Symptoms management (e.g. Pain, nausea, dehydration management).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Description: Nutritional status evaluation and dietary supplementation according to the patient requirements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation.
Description: Patient and care-taker psychoeducation, depression and anxiety evaluation.
Study: NCT02576249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 4cc 0.5% ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: 4cc of sterile normal saline (0.9%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 1cc 40mg methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 1cc 40mg methylprednisolone
Study: NCT01284439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxypropylmethylcellulose
Description: TearA: QID to every 2 hous , 1-2 drops per each time , duration 1 month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium hyaluronate
Description: QID to every 2 hous, 1-2 drops per each time, duration 1 month
Study: NCT00242866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW274150
Description: The tablets used in this study will contain either 5mg or 30mg of GW274150

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW274150
Description: The tablets used in this study will contain either 5mg or 30mg of GW274150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to Match GW274150

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Match GW274150
Study: NCT03533465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complicated Grief Therapy (CGT)
Description: CGT is an evidence based 16 session targeted grief therapy delivered in individual one hour weekly sessions. Treatment will end at 16 sessions (offered over the course of 20 weeks)
Study: NCT03157622

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure in vivo
Description: 10 sessions based on an individualized fear hierarchy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Psychotherapy
Description: graded activity, relaxation techniques and cognitive interventions
Study: NCT03633890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DaZhu Rhodiola Rosea Capsule
Description: Oral administration, 4 capsules, 3 times a day, for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DaZhu Rhodiola Rosea Simulation Capsule
Description: Oral administration, 4 capsules, 3 times a day, for 8 weeks
Study: NCT00090857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02122796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture involves inserting thin, sterile needles into the skin at certain points in the body.
Study: NCT01551095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEGJ tube
Description: The self-propelled PEGJ feeding tube
Study: NCT01739790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine
Description: 1800 mg twice daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo manufactured to mimic appearance of intervention drug with identical frequency and duration.
Study: NCT01719406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention, behavioral lifestyle education
Description: Twenty interactive weekly sessions that are scripted curriculum and peer led.
Study: NCT00193037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Description: Liposomal Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel
Study: NCT03343522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A multimodal exercise training program (aerobic, strength and flexibility exercises) for 6 months (60-min sessions performed 3 times/week with moderate intensity).
Study: NCT04528420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: optimised management
Description: At the inclusion , the patient will benefit from an early consultation with a nutritionist, a pain doctor and a social worker.~During the preparation phase for radiotherapy the patient will benefit from weekly consultations with a pain nurse and a dietician.~During the radiotherapy the patient will be weighed daily and have an assessment of their nutritional needs and a weekly consultation with a pain nurse and dietician and then twice a month until three months post-radiotherapy.
Study: NCT02001948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine 0.1 mg combined with intrathecal heavy bupivacaine 7.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine 0.4 mg combined with intrathecal heavy bupivacaine 7.5 mg

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard monitoring with Datex Ohmeda anesthesia monitor, GE, Finland
Description: electrocardiography, heart rate, pulse oximetry and noninvasive arterial blood pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard monitoring with Datex Ohmeda anesthesia monitor, GE, Finland
Description: electrocardiography, heart rate, pulse oximetry and noninvasive arterial blood pressure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous cannulation and premedication
Description: 18-gauge intravenous cannula was inserted at the forearm opposite to the surgical side and routine iv premedication (midazolam 0.03 mg/kg) was given

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous cannulation and premedication
Description: 18-gauge intravenous cannula was inserted at the forearm opposite to the surgical side and routine iv premedication (midazolam 0.03 mg/kg) was given
Study: NCT02359305

Intervention type: DRUG
Intervention: Acetaminophen
Description: Acetaminophen given by IV

Intervention type: DRUG
Intervention: Acetaminophen
Description: Acetaminophen suppository given rectally
Study: NCT02462330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous MSC from bone marrow
Description: After bone-marrow aspiration by an authorized person, MSCs were isolated and cultured during 17±2 days by the French Blood Establishment. Then, patients receive intramyocardial injections of MSCs using the electromechanical NOGA-XP system.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: injections of human albumin
Study: NCT01543880

Intervention type: DRUG
Intervention: somatropin
Description: Prescribed at the discretion of the treating physician according to product labelling
Study: NCT02506309

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOT - inside-out trans-obturator tape/sling
Description: Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIS - Innovative fixation single incision sling
Description: Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)
Study: NCT04326998

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: solvent
Description: using solvent (GuttaClear) in procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-solvent
Description: non-solvent
Study: NCT02601495

Intervention type: BEHAVIORAL
Intervention: Women in a court diversion program
Description: Women in Recovery (WIR) is an intensive outpatient alternative for eligible women facing long prison sentences for non-violent, drug-related offenses in Oklahoma.
Study: NCT01076452

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Deep Brain Stimulation
Description: The DBS site (STN or GPi) was assigned on a random basis at the time the patient enters the surgical phase of the trial.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Deep Brain Stimulation
Description: The DBS site (STN or GPi) was assigned on a random basis at the time the patient enters the surgical phase of the trial.
Study: NCT03865654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Tool
Description: Summarizes recommendations for clinicians and patients for surveillance mammography and follow-up care for breast cancer survivors
Study: NCT01434108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ornithine-phenylacetate
Description: Phase A: Open-label scalating dose of OP. Treatment will be initiated at 1/3 of the final dose and will be scalated every 12 hours up to the full dose, except if there are problems of tolerance. Duration of the infusion 5 days.~Phase B: Comparative study of experimental drug vs placebo for 5 days OP (OCR-002) at a dose of 10 g diluted in 150 ml of water for injection administered as a continuous i.v. infusion for 24 hours (8.3 ml/h)during 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ornithine-phenylacetate
Description: Phase A: Open-label scalating dose of OP. Treatment will be initiated at 1/3 of the final dose and will be scalated every 12 hours up to the full dose, except if there are problems of tolerance. Duration of the infusion 5 days.~Phase B: Comparative study of experimental drug vs placebo for 5 days OP (OCR-002) at a dose of 10 g diluted in 150 ml of water for injection administered as a continuous i.v. infusion for 24 hours (8.3 ml/h)during 5 days.
Study: NCT03437356

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation using CLOSE protocol
Description: 'CLOSE' protocol: Ablation index \> 400 at the posterior wall (reduce to 300 if esophagus temperature rise), ablation index \> 550 at the anterior wall, and inter-lesion distance \< 6.0mm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation using CLOSE protocol
Description: 'CLOSE' protocol: Ablation index \> 400 at the posterior wall (reduce to 300 if esophagus temperature rise), ablation index \> 550 at the anterior wall, and inter-lesion distance \< 6.0mm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drug therapy (ADT)
Description: During the first 3 months after PVI, patients continue oral anticoagulants and antiarrhythmic drug therapy (ADT). ADT is a continuation (or restart) of previously ineffective Class IC and III ADT. At the time of discharge, dosage is optimized according to the 2016 ESC guidelines on AF management.~Preferred dosages:~Flecainide: Tambocor or Flecainide EG 100mg b.i.d., Apocard R 100 to 200mg overdose (OD) Propafenone: Rytmonorm or Propafenone EG 300 mg b.i.d., except 225 mg b.i.d. if ≥70 years or \<70 kg Sotalol: Sotalex or Sotalol EG 80mg b.i.d., Except 80mg t.i.d. if men \< 70 years, Cr \<1.5mg/dl, \>70kg, except 80 mg OD if female \>70 years or Cr \>1.2mg/dl~In case of amiodarone intake before PVI, amiodarone is switched to sotalol or class IC ADT.
Study: NCT02550574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound Closure with 2-octylcyanoacrylate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Closure with 2-octylcyanoacrylate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound Closure with 5-0 Vicryl Sutures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Closure with 5-0 Vicryl Sutures
Study: NCT04465409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrastromal implantation of CorVision bioengineered corneal inlay for correction of presbyopia.
Description: Presbyopia is an age-related progressive loss of crystalline lens accommodation power resulting in the decreased ability to see near objects. CorVision® is a tissue-mimetic device primarily intended to be used as a corneal inlay in the management of presbyopia and low hypermetropia. The inlay is inserted into the patient's cornea via a minimally invasive laser pocket procedure to modify corneal surface topography and corneal optical performance.
Study: NCT00913705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (taxol and carboplatin)
Description: Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21-day intervals. Prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (taxol and carboplatin)
Description: Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21 days interval. Post-surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery
Study: NCT01781637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection
Study: NCT04353791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OST-122
Description: Active dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02377622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERANOVA 400 dialyzer prototype AA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERANOVA 400 dialyzer prototype BB

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FX CorDiax 80 Dialyzer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FX CorDiax 800 Dialyzer
Study: NCT02060110

Intervention type: DEVICE
Intervention: Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study

Intervention type: DEVICE
Intervention: MADIT-CRT ICD ONLY ARM
Study: NCT02352298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dario Blood Glucose Monitoring System
Description: Fingerstick to obtain blood sample for analysis with the Dario BGMS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: YSI Analyzer
Description: Fingerstick to obtain blood sample for analysis with YSI